Cellectis S.A. (NASDAQ:CLLS - Get Free Report)'s share price crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $1.61 and traded as low as $1.39. Cellectis shares last traded at $1.40, with a volume of 59,824 shares changing hands.
Wall Street Analysts Forecast Growth
A number of brokerages recently issued reports on CLLS. StockNews.com initiated coverage on shares of Cellectis in a report on Thursday. They issued a "buy" rating for the company. Barclays lowered their price objective on Cellectis from $7.00 to $5.00 and set an "overweight" rating for the company in a research report on Tuesday, November 5th.
Check Out Our Latest Research Report on CLLS
Cellectis Stock Performance
The stock has a fifty day moving average of $1.60 and a 200-day moving average of $1.88. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. The stock has a market cap of $71.70 million, a PE ratio of -0.99 and a beta of 3.06.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. Wells Fargo & Company MN grew its holdings in Cellectis by 103.4% during the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock worth $44,000 after acquiring an additional 12,500 shares during the period. Millennium Management LLC acquired a new position in shares of Cellectis in the fourth quarter worth $962,000. Finally, B Group Inc. acquired a new position in shares of Cellectis in the fourth quarter worth $5,547,000. Institutional investors and hedge funds own 63.90% of the company's stock.
About Cellectis
(
Get Free Report)
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
See Also
Before you consider Cellectis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellectis wasn't on the list.
While Cellectis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
